Hepatorenal Syndrome — Viva

Q1: Definition and the diagnosis of exclusion (3 min)

Examiner: Define hepatorenal syndrome. Why is it called a diagnosis of exclusion?^[1]

Candidate: Hepatorenal syndrome is a functional, potentially reversible form of acute kidney injury that develops in patients with advanced cirrhosis and ascites (or acute liver failure or acute-on-chronic liver failure), in the absence of any other identifiable renal injury. The kidneys are structurally normal — they recover after liver transplantation or, in selected cases, after pharmacological correction of splanchnic vasodilation. It is a diagnosis of exclusion: cirrhosis with ascites; AKI by the ICA-aligned creatinine definition (rise of at least 0.3 mg/dL within 48 hours or at least 50 percent within 7 days; urine output and FeNa have significant limitations); no response after diuretic withdrawal and albumin 1 g/kg (maximum 100 g) for two consecutive days; no shock, nephrotoxin, obstruction or structural kidney injury (no significant proteinuria). Mnemonic for the three exclusions: "No Shock, No Drug, No Structure."^[1][3]

Q2: Pathophysiology — the peripheral arterial vasodilation hypothesis (3 min)

Examiner: Walk me through the mechanism of HRS.^[1]

Candidate: The dominant mechanism is the peripheral arterial vasodilation hypothesis. Portal hypertension from increased intrahepatic vascular resistance triggers progressive splanchnic arterial vasodilation mediated by nitric oxide, carbon monoxide and endocannabinoids, causing a fall in systemic vascular resistance and a reduced effective arterial blood volume. Baroreceptors and the juxtaglomerular apparatus sense the underfilled arterial tree and activate three systems: the renin-angiotensin-aldosterone system, the sympathetic nervous system, and non-osmotic arginine vasopressin. This produces intense renal arterial vasoconstriction, avid sodium and water retention (ascites, dilutional hyponatraemia), and a falling GFR. Protective prostaglandin-mediated vasodilation is insufficient to maintain renal perfusion — which is why NSAIDs, which inhibit those prostaglandins, are hazardous. A second hit — cirrhotic cardiomyopathy reducing cardiac output, or an inflammatory/infectious insult such as SBP — overwhelms the vasoconstrictor reserve. The kidney is structurally normal throughout, which is why it recovers after transplantation.^[1]

Q3: Distinguishing HRS from other causes of AKI in cirrhosis (3 min)

Examiner: How do you distinguish HRS from volume-responsive pre-renal AKI and from acute tubular necrosis?^[19]

Candidate: This is the central bedside and exam task. Volume-responsive pre-renal AKI improves after diuretic withdrawal and albumin 1 g/kg (maximum 100 g) for two consecutive days — HRS does not. Do not use FeNa to prove either diagnosis: in a prospective cirrhosis-AKI cohort, median FeNa was 0.10 percent in HRS, 0.27 percent in volume-responsive pre-renal AKI, and 0.31 percent in ATN (no difference between pre-renal and ATN). A FeNa over 2 percent is therefore not a reliable ATN marker in cirrhosis. ATN is suggested by a clear ischaemic, nephrotoxic or septic insult and muddy brown casts, not by a urine-sodium cut-off. Glomerular disease has significant proteinuria or haematuria — none in HRS. Obstruction is excluded by ultrasound. The sequence is: ascitic tap, albumin challenge, urine microscopy and proteinuria, ultrasound, and a nephrotoxin review. Vasoconstrictors are not justified for ATN; HRS and ATN are increasingly seen as a continuum.^[19][3]

Q4: Pharmacotherapy and the CONFIRM trial (3 min)

Examiner: Outline the definitive pharmacotherapy for HRS, and tell me what the CONFIRM trial changed.^[5]

Candidate: Definitive pharmacotherapy is terlipressin plus albumin. Bolus 0.5 to 1 mg every 4 to 6 hours, increased to a maximum of 2 mg every 4 hours if no response, or continuous infusion 2 to 12 mg/day, plus albumin 1 g/kg on day 1 then 20 to 40 g/day, for up to 14 days. Target verified reversal: two creatinine values of 1.5 mg/dL or less at least 2 hours apart, plus survival free of RRT for at least 10 days. CONFIRM (Wong et al., NEJM 2021) showed verified reversal 32 percent versus 17 percent with placebo, but 90-day death 51 versus 45 percent and death from respiratory disorders 11 versus 2 percent — so it is a renal-reversal trial, not a mortality win. Terlipressin is contraindicated in hypoxaemia and ongoing coronary, peripheral or mesenteric ischaemia; it does not require ICU monitoring and can run through a peripheral line. Noradrenaline 0.5 to 3.0 mg/hour plus albumin is a cheaper ICU alternative (50 percent reversal in a 40-patient Indian pilot). Midodrine plus octreotide recovered renal function in 28.6 versus 70.4 percent against terlipressin.^[5][3][6]

Q5: Prevention and the Sort trial (2 min)

Examiner: How do you prevent hepatorenal syndrome?^[4]

Candidate: Prevention is the most practical intervention, especially where transplant access is limited. The bundle: primary SBP prophylaxis with norfloxacin in high-risk low-protein ascites (under 15 g/L) plus advanced liver failure or impaired renal function — this reduced one-year SBP from 61 to 7 percent, delayed HRS (28 versus 41 percent), and improved survival; albumin 8 g per litre of ascites removed when more than 5 L is tapped (EASL); the Sort regimen — albumin 1.5 g/kg day 1 and 1 g/kg day 3 with cefotaxime after SBP (renal impairment 10 versus 33 percent, in-hospital mortality 10 versus 29 percent); avoid NSAIDs and other nephrotoxins; treat GI bleeds with vasoactive drugs started as soon as variceal haemorrhage is suspected. Do not use albumin as a tonic for uncomplicated ascites, and do not use vasoconstrictors for uncomplicated ascites, after LVP, or in SBP.^[12][15][4]

Q6: Prognosis and transplantation (2 min)

Examiner: What is the prognosis of HRS, and what is the role of transplantation?^[10]

Candidate: Untreated HRS in cirrhosis with ascites is associated with extremely short survival. Pooled series reported renal-function improvement in 35 to 45 percent with terlipressin plus albumin; CONFIRM verified reversal in 32 versus 17 percent without a 90-day mortality benefit (51 versus 45 percent died). Even responders carry very high early mortality without liver transplantation, which is the only cure. Pretransplant terlipressin plus albumin decreased the need for RRT both before and after transplant. Independent predictors of HRS occurrence are low serum sodium, high plasma renin activity, and absence of hepatomegaly; AGA cautions that terlipressin benefits may not outweigh risks when creatinine exceeds 5 mg/dL or MELD is 35 or higher.^[10][5][15]

References19ShowHide

1. [1]Girish V, Ranasinghe IR, Rout P Hepatorenal Syndrome StatPearls [Internet], 2026.PMID 28613606
2. [2]Angeli P, Garcia-Tsao G, Nadim MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document J Hepatol, 2019.PMID 31302175
3. [3]Francoz C, Durand F, Kahn JA, Nadim MK Hepatorenal Syndrome Clin J Am Soc Nephrol, 2019.PMID 30996046
4. [4]Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis N Engl J Med, 1999.PMID 10432325
5. [5]Wong F, Pappas SC, Curry MP, et al. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome N Engl J Med, 2021.PMID 33657294
6. [6]Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial Hepatology, 2015.PMID 25644760
7. [7]Cavallin M, Fasolato S, Marenco S, Piano S, Tonon M, Angeli P The Treatment of Hepatorenal Syndrome Dig Dis, 2015.PMID 26159272
8. [8]Sharma P, Kumar A, Sharma BC, Sarin SK An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response Am J Gastroenterol, 2008.PMID 18557715
9. [9]Guevara M, Ginès P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems Hepatology, 1998.PMID 9696006
10. [10]Ginès A, Escorsell A, Ginès P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites Gastroenterology, 1993.PMID 8514039
11. [11]Ginès P, Titó L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis Gastroenterology, 1988.PMID 3360270
12. [12]Fernández J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis Gastroenterology, 2007.PMID 17854593
13. [13]Caregaro L, Menon F, Angeli P, et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis Arch Intern Med, 1994.PMID 8285815
14. [14]Khemichian S, Francoz C, Nadim MK Advances in management of hepatorenal syndrome Curr Opin Nephrol Hypertens, 2021.PMID 34397647
15. [15]Garcia-Tsao G, Abraldes JG, Rich NE, et al. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review Gastroenterology, 2024.PMID 37978969
16. [16]Best LM, Freeman SC, Sutton AJ, et al. Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis Cochrane Database Syst Rev, 2019.PMID 31513287
17. [17]Weinberg EM, Wong F, Vargas HE, et al. Decreased need for RRT in liver transplant recipients after pretransplant treatment of hepatorenal syndrome-type 1 with terlipressin Liver Transpl, 2024.PMID 37801553
18. [18]European Association for the Study of the Liver EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis J Hepatol, 2018.PMID 29653741
19. [19]Belcher JM, Sanyal AJ, Peixoto AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury Hepatology, 2014.PMID 24375576